Literature DB >> 19899133

BH3-only proteins: the death-puppeteer's wires.

Fabio Ghiotto1, Franco Fais, Silvia Bruno.   

Abstract

Most cell death in vertebrates proceeds through the intrinsic pathway of apoptosis and results from unregulated increase of mitochondrial membrane permeability. Bcl2-associated X protein (Bax) and Bcl2-antagonist/killer protein (Bak), the effector proapoptotic members of the Bcl-2 family, are, in their active state, the principal accomplices for this permeabilization process. How exactly Bax and Bak are activated has been a matter of major investigation in the last decade, and suitable tools offered by quantitative cytometric methodologies have significantly contributed to the understanding of the function of Bcl-2 family members. Here, we review the most relevant findings in this field and highlight one common trait that has emerged from the diverse new theories: a crucial role in the control of Bax/Bak activation has to be attributed to the BH3-only subset of the Bcl-2 family. BH3-only proteins exert their proapoptotic activity by hierarchical and tightly tuned interactions with other Bcl-2 family members and operate as sensors of intracellular/extracellular death signals and vectors of information to the core apoptotic machinery. Given their essential role in apoptosis, BH3-only molecules are proposed as molecular targets for the cure of diseases associated with abnormal cell death, as in the case with neurodegenerative conditions. As well, they are explored as possible tools for cancer therapy, according to the concept that molecules mimicking the BH3 domain of these proteins could selectively and efficiently cooperate in the cell killing by chemotherapeutic drugs. A few BH3 mimetics are currently being tested in clinical trials of hematologic and solid tumors. Nevertheless, the knowledge about the cellular and molecular mechanisms that regulate responsiveness to BH3 therapy has to be further expanded and will benefit from recent advances in cytometric quantitative technologies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19899133     DOI: 10.1002/cyto.a.20819

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  21 in total

1.  Structural changes in the BH3 domain of SOUL protein upon interaction with the anti-apoptotic protein Bcl-xL.

Authors:  Emmanuele Ambrosi; Stefano Capaldi; Michele Bovi; Gianmaria Saccomani; Massimiliano Perduca; Hugo L Monaco
Journal:  Biochem J       Date:  2011-09-01       Impact factor: 3.857

2.  C-peptide preserves the renal microvascular architecture in the streptozotocin-induced diabetic rat.

Authors:  Elizabeth R Flynn; Jonathan Lee; Zachary M Hutchens; Alejandro R Chade; Christine Maric-Bilkan
Journal:  J Diabetes Complications       Date:  2013-08-29       Impact factor: 2.852

3.  Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response.

Authors:  Devon B Oskvig; Abdel G Elkahloun; Kory R Johnson; Terry M Phillips; Miles Herkenham
Journal:  Brain Behav Immun       Date:  2012-01-30       Impact factor: 7.217

4.  RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines.

Authors:  Jane Levesley; Meryl E Lusher; Janet C Lindsey; Steven C Clifford; Richard Grundy; Beth Coyle
Journal:  Neuro Oncol       Date:  2011-08-31       Impact factor: 12.300

Review 5.  Defining the roles for Vpr in HIV-1-associated neuropathogenesis.

Authors:  Tony James; Michael R Nonnemacher; Brian Wigdahl; Fred C Krebs
Journal:  J Neurovirol       Date:  2016-04-07       Impact factor: 2.643

6.  Bid is a positive regulator for donor-derived lymphoid cell regeneration in γ-irradiated recipients.

Authors:  Hongmei Shen; Hui Yu; Paulina H Liang; Richard Xufeng; Yifang Song; Xiaoxia Hu; Xiaoyun Chen; Xiao-Ming Yin; Tao Cheng
Journal:  Exp Hematol       Date:  2011-06-16       Impact factor: 3.084

Review 7.  Apoptotic cell signaling in cancer progression and therapy.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  Integr Biol (Camb)       Date:  2011-02-22       Impact factor: 2.192

8.  Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells.

Authors:  Yan Liu; Shi-Yong Sun; Taofeek K Owonikoko; Gabriel L Sica; Walter J Curran; Fadlo R Khuri; Xingming Deng
Journal:  Mol Cancer Ther       Date:  2011-11-04       Impact factor: 6.261

Review 9.  Emerging Bcl-2 inhibitors for the treatment of cancer.

Authors:  Asfar S Azmi; Zhiwei Wang; Philip A Philip; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Expert Opin Emerg Drugs       Date:  2010-09-03       Impact factor: 4.191

Review 10.  On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.

Authors:  L Y Dimberg; C K Anderson; R Camidge; K Behbakht; A Thorburn; H L Ford
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.